Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Research and Development Grants

University of Guelph

$53,480.00

Investigating mechanisms of action of silver oxynitrate: an unexplored silver compound with superior anti-biofilm activity.

FY 2017-18

Summary
Silver has been used as an antimicrobial compound for thousands of years. Although interest in silver waned in the 1940s with the advent of antibiotic technologies, incidence of antibiotic resistance led to a resurgence in silver antimicrobial technologies in the 1980s. Since then, a variety of silver compounds have been used in topical antimicrobial applications, however, there is still no consensus on the efficacy of silver and mechanistic studies of silver activity are restrictive to singly ionic silver. As a consequence, silver compounds have a tarnished reputation. This project will be the first investigation into mechanisms of action and resistance for a range of silver compounds including the novel silver oxynitrate. Differentiating silver mechanisms of action and antimicrobial resistance will provide a greater understanding of efficacy, establishing structure for consensus, clinical use, and new technological developments. These findings will provide clinicians and patients with effective options for the management of antibiotic resistant infections. Resulting in lessened incidence of infection and associated costs, currently estimated at CAD$ 1 Billion, within the Canadian Health Care System.
Program
Collaborative Research and Development Grants
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
501022-2016
Name nom
Khursigara, Cezar
Department département
Molecular and Cellular Biology
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2016
Award amount
53480
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5300
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Molecular biology
Research subject fr
Biologie moléculaire
Partie
1
Nb partie
2
Application title
Investigating mechanisms of action of silver oxynitrate: an unexplored silver compound with superior anti-biofilm activity.
Keyword
NSERC
Application summary
Silver has been used as an antimicrobial compound for thousands of years. Although interest in silver waned in the 1940s with the advent of antibiotic technologies, incidence of antibiotic resistance led to a resurgence in silver antimicrobial technologies in the 1980s. Since then, a variety of silver compounds have been used in topical antimicrobial applications, however, there is still no consensus on the efficacy of silver and mechanistic studies of silver activity are restrictive to singly ionic silver. As a consequence, silver compounds have a tarnished reputation. This project will be the first investigation into mechanisms of action and resistance for a range of silver compounds including the novel silver oxynitrate. Differentiating silver mechanisms of action and antimicrobial resistance will provide a greater understanding of efficacy, establishing structure for consensus, clinical use, and new technological developments. These findings will provide clinicians and patients with effective options for the management of antibiotic resistant infections. Resulting in lessened incidence of infection and associated costs, currently estimated at CAD$ 1 Billion, within the Canadian Health Care System.